Paper Details
- Home
- Paper Details
Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Author: HosoiAkihiro, KakimiKazuhiro, KarasakiTakahiro, KawaiTaketo, KobayashiYukari, KumeHaruki, MatsumotoAkihiko, MatsushitaHirokazu, NagaokaKoji, NakagawaTohru, NakamuraMasaaki, SatoYusuke, SuzukiMotofumi, TeshimaTaro, YamadaDaisuke, YamadaYuta
Original Abstract of the Article :
Treatment with molecular targeted agents together with immune checkpoint inhibitors will most likely improve the efficacy of current cancer immunotherapy. Because molecular targeted agents not only directly affect cancer cells, but also influence immune cells and modulate the tumor microenvironment,...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.3892/ijo.2020.4975
データ提供：米国国立医学図書館（NLM）
Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma
This research delves into the exciting world of immunotherapy, exploring the potential of using the body's own immune system to fight cancer. Imagine a camel caravan encountering a group of predators - cancer cells are like persistent threats that need to be neutralized. This research examines the immunological effects of three molecular targeted agents, sunitinib, everolimus, and temsirolimus, used to treat renal cell carcinoma (RCC).Understanding the impact of targeted therapies on the immune system
This research reveals that these targeted agents exert different effects on the immune system, highlighting the importance of a personalized approach to cancer treatment. Just as a skilled caravan leader understands the unique characteristics of each camel in their group, researchers are seeking to understand the individual responses of patients to different therapies. The study investigates how these agents influence the activity of immune cells, including T cells, natural killer cells, and myeloid-derived suppressor cells.Optimizing cancer treatment through immunomodulation
This research suggests that combining molecular targeted agents with immune checkpoint inhibitors could enhance the effectiveness of cancer immunotherapy. Imagine a caravan leader strategically using different tactics to overcome obstacles and protect their camels. This study emphasizes the need for a comprehensive understanding of how these agents interact with the immune system to develop more effective and personalized treatment strategies.Dr.Camel's Conclusion
This research sheds light on the complex interplay between targeted therapies and the immune system in cancer treatment. Just as a caravan leader navigates a desert landscape, understanding the nuances of the immune response is crucial for developing effective and personalized strategies to combat cancer.Date :
- Date Completed 2021-02-19
- Date Revised 2021-09-17
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.